{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33355186",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "10",
    "Day": "05"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "12",
        "Day": "21"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1158/0008-5472.CAN-20-3691"
    ],
    "Journal": {
      "ISSN": "1538-7445",
      "JournalIssue": {
        "Volume": "81",
        "Issue": "5",
        "PubDate": {
          "Year": "2021",
          "Month": "Mar",
          "Day": "01"
        }
      },
      "Title": "Cancer research",
      "ISOAbbreviation": "Cancer Res"
    },
    "ArticleTitle": "Is COVID-19-Induced Platelet Activation a Cause of Concern for Patients with Cancer?",
    "Pagination": {
      "StartPage": "1209",
      "EndPage": "1211",
      "MedlinePgn": "1209-1211"
    },
    "Abstract": {
      "AbstractText": [
        "Patients with cancer are more susceptible to be infected by SARS-CoV-2 and develop severe outcomes including ICU admittance, mechanical ventilator support, and a high rate of mortality. Like mid-to late-stage cancer, SARS-CoV-2 infection is associated with platelet hyperactivity, systemic inflammation, thrombotic complications, and coagulopathy. Platelets also promote cancer cell growth, survival in circulation, and angiogenesis at sites of metastases. In this article, we will discuss the potential for platelets in the development of systemic inflammation and thrombosis in SARS-CoV-2-infected patients with cancer, with the concern that the platelet-induced pathogenic events are likely magnified in cancer patients with COVID-19."
      ],
      "CopyrightInformation": "\u00a92020 American Association for Cancer Research."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas. lenard.m.lichtenberger@uth.tmc.edu vvijayan@bcm.edu."
          }
        ],
        "LastName": "Lichtenberger",
        "ForeName": "Lenard M",
        "Initials": "LM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Baylor College of Medicine and Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey, Veterans Affairs Medical Center, Houston, Texas. lenard.m.lichtenberger@uth.tmc.edu vvijayan@bcm.edu."
          }
        ],
        "LastName": "Vijayan",
        "ForeName": "K Vinod",
        "Initials": "KV"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R21 CA182798",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R42 CA171408",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R41 CA171408",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA247917",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R03 CA171613",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cancer Res",
    "NlmUniqueID": "2984705R",
    "ISSNLinking": "0008-5472"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Blood Platelets"
    },
    {
      "QualifierName": [
        "diagnosis",
        "physiopathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "physiopathology"
      ],
      "DescriptorName": "Inflammation"
    },
    {
      "QualifierName": [
        "diagnosis",
        "physiopathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Platelet Activation"
    },
    {
      "QualifierName": [
        "methods",
        "statistics & numerical data"
      ],
      "DescriptorName": "Risk Assessment"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [
        "isolation & purification",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "physiopathology"
      ],
      "DescriptorName": "Thrombosis"
    }
  ],
  "CoiStatement": "<b>Disclosure of potential conflicts of interest:</b> Dr. Lichtenberger is a co-founder of and shareholder in PLx Pharma Inc that is developing a phosphatidylcholine -associated aspirin for cardiovascular indications. Dr. Vijayan has no potential conflicts of interest."
}